ReviewFrontiers in psychiatry2025
Everyday stress-induced neurobehavioral dysregulation: therapeutic targets for management with Neurexan.
Review in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chemical characterization of Nurexan: composition of a multicomponent natural veterinary medicinal product.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Everyday stress is highly prevalent and can impact human health, performance, well-being, and mortality risk. Despite being widely acknowledged, everyday stress is rarely assessed or treated, highlighting a critical gap in clinical routine. To better understand the relevance of everyday stress for healthcare professionals, we use the Research Domain Criteria (RDoC) framework to link stress neurobiology to its behavioral signs and symptoms. According to RDoC, everyday stress is conceptualized as impacting domains of basic neurobiological functioning. Everyday stress influences two primary domains - the negative valence domain, and arousal and regulatory systems - that can, in turn, lead to mental and physical health problems. Neurexan, a natural multi-component medication, targets these two domains. We review recent data on how Neurexan can mitigate the negative impact of stress on the negative valence domain and regulate arousal, thus helping to restore neurobiological and clinical functioning. This review provides an overview of relevant aspects of stress, mainly everyday stress, and the latest research on Neurexan as a potential option to target everyday stress. More broadly, this work may lead to new methods of assessing and managing everyday stress to improve the psychosocial resilience and well-being of individuals facing difficulty coping with repetitive or chronic stress in their daily lives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.